Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2022 - 2024)

Amylyx Pharmaceuticals' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $37.0 million for Q3 2024.

• On a quarterly basis, Other Operating Expenses rose 609.31% year-over-year to $37.0 million in Q3 2024; TTM through Jun 2025 was $37.0 million, a 73.26% decrease from a year earlier, with the FY2024 full-year figure at $160.8 million, up 532.19% from the prior year.
• Other Operating Expenses rose to $37.0 million in Q3 2024 per AMLX's latest filing, from $7.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $116.4 million in Q1 2024 and bottomed at $172000.0 in Q3 2022.
• The 3-year median for Other Operating Expenses is $5.6 million (2023), against an average of $21.0 million.
• Across the five-year window, Other Operating Expenses surged 2933.72% in 2023 and jumped 32.94% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $2.8 million in 2022, then soared by 231.8% to $9.4 million in 2023, then soared by 295.43% to $37.0 million in 2024.
• Per Business Quant, the three latest AMLX Other Operating Expenses figures stand at $37.0 million (Q3 2024), $7.4 million (Q2 2024), and $116.4 million (Q1 2024).